Featured Research

from universities, journals, and other organizations

Drugs used to treat HIV also reduce risk of HIV infection, review suggests

Date:
July 11, 2012
Source:
Wiley
Summary:
People at high risk of HIV infection can reduce their risk of acquiring the disease by taking antiretroviral drugs, according to Cochrane researchers. In an update of a systematic review first published in 2009, the researchers found that uninfected people in relationships with HIV-infected partners, men who have sex with men and those in other high risk groups are at a lower risk of becoming infected with the virus if they regularly take drugs that are normally prescribed to treat people with HIV.

People at high risk of HIV infection can reduce their risk of acquiring the disease by taking antiretroviral drugs, according to Cochrane researchers. In an update of a systematic review first published in 2009, the researchers found that uninfected people in relationships with HIV-infected partners, men who have sex with men and those in other high risk groups are at a lower risk of becoming infected with the virus if they regularly take drugs that are normally prescribed to treat people with HIV.

Antiretroviral therapy (ART) is the standard drug treatment for HIV in patients whose disease has progressed to a certain level. Antiretroviral drugs are also beginning to be used as prophylactics in people at high risk of acquiring the disease from sexual partners. The use of antiretroviral drugs in preventing as opposed to treating HIV infection is referred to as pre-exposure prophylaxis (PrEP). PrEP is often considered controversial, not only because uninfected people may develop resistance to the drugs and experience serious side effects such as kidney toxicity and bone density loss, but also because the idea that PrEP offers protection may encourage people to indulge in riskier sexual behaviour, thereby increasing their overall risk of HIV infection. It is therefore important to establish whether PrEP really works and what level of protection it affords.

The researchers analysed data from six trials that tested the protective effect of daily doses of the oral antiretroviral drug tenofovir disoproxil fumarate (TDF) with or without emtricitabine (FTC), compared to a placebo or intermittent use. In total, the trials involved 9,849 people, including men who have sex with men, partners of HIV-infected people, sex workers and people who have multiple sexual partners. Data from four of the trials and a total of 8,813 people showed that giving TDF plus FTC reduces the risk of HIV infection by around half, from 37 in 1,000 to 19 in 1,000. Data from two trials and a total of 4,027 people showed that TDF alone reduces the risk of HIV infection by nearly two thirds, from 26 in 1,000 to 10 in 1,000.

"Our findings suggest that antiretroviral drugs can reduce the risk of HIV infection for people in high risk groups," said lead researcher, Charles Okwundu of the Centre for Evidence-Based Health Care at Stellenbosch University in Tygerberg, South Africa. "However, in the search for highly reliable HIV prevention strategies, it is important to determine how pre-exposure prophylaxis can best be combined with existing programmes, as no strategy is likely to be 100 per cent effective."

Those taking antiretroviral drugs did not suffer more adverse effects in the trials, and sexual risk behaviour was similar in both the intervention and control groups. But the researchers say further research is required to ensure that PrEP, which is still a new approach, is safe and cost-effective. "There are still many questions that need to be answered," said Okwundu. "For example, how do we ensure that people adhere to their ART regimens? What are the long-term effects? Is pre-exposure prophylaxis cost-effective in the long run?"


Story Source:

The above story is based on materials provided by Wiley. Note: Materials may be edited for content and length.


Journal Reference:

  1. Charles I Okwundu, Olalekan A Uthman, Christy AN Okoromah. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Review, 2012 DOI: 10.1002/14651858.CD007189.pub3

Cite This Page:

Wiley. "Drugs used to treat HIV also reduce risk of HIV infection, review suggests." ScienceDaily. ScienceDaily, 11 July 2012. <www.sciencedaily.com/releases/2012/07/120711074320.htm>.
Wiley. (2012, July 11). Drugs used to treat HIV also reduce risk of HIV infection, review suggests. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2012/07/120711074320.htm
Wiley. "Drugs used to treat HIV also reduce risk of HIV infection, review suggests." ScienceDaily. www.sciencedaily.com/releases/2012/07/120711074320.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins